Molecular action of methotrexate in inflammatory diseases

Despite the recent introduction of biological response modifiers and potent new small-molecule antirheumatic drugs, the efficacy of methotrexate is nearly unsurpassed in the treatment of inflammatory arthritis. Although methotrexate was first introduced as an antiproliferative agent that inhibits the synthesis of purines and pyrimidines for the therapy of malignancies, it is now clear that many of the anti-inflammatory effects of methotrexate are mediated by adenosine. This nucleoside, acting at one or more of its receptors, is a potent endogenous anti-inflammatory mediator. In confirmation of this mechanism of action, recent studies in both animals and patients suggest that adenosine-receptor antagonists, among which is caffeine, reverse or prevent the anti-inflammatory effects of methotrexate.

• Publication year

  2002

• Venue

  Arthritis Research

• Publication date

  2002-03-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/AR419PMID 12106498PMCID 128935
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression.

  2010cited by this paper
• Analysis of randomized controlled trials.

  2002cited by this paper
• Cyclic AMP‐dependent inhibition of human neutrophil oxidative activity by substituted 2‐propynylcyclohexyl adenosine A2A receptor agonists

  2001cited by this paper
• Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.

  2001cited by this paper
• Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis: An update and proposals for guidelines

  2001cited by this paper
• Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis

  2001cited by this paper
• Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation.

  2001cited by this paper
• Inflammatory Cytokines Regulate Function and Expression of Adenosine A2A Receptors in Human Monocytic THP-1 Cells1

  2001cited by this paper
• Methotrexate inhibits rheumatoid synovitis by inducing apoptosis.

  2001cited by this paper
• Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation.

  2001cited by this paper
• Protein tyrosine phosphatase-dependent proteolysis of focal adhesion complexes in endothelial cell apoptosis.

  2001cited by this paper
• Methotrexate Suppresses NF-κB Activation Through Inhibition of IκBα Phosphorylation and Degradation1

  2001cited by this paper
• Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.

  2001cited by this paper
• Anti-cytokine therapy in chronic destructive arthritis

  2000cited by this paper
• Anti-cytokine therapy in chronic destructive arthritis

  2000cited by this paper
• Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor.

  2000cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Suppression of TNF‐α production in human mononuclear cells by an adenosine kinase inhibitor

  2000cited by this paper
• Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.

  2000cited by this paper
• Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis.

  2000cited by this paper
• Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4.

  2000cited by this paper
• Methotrexate for rheumatoid arthritis.

  2000cited by this paper
• Macrophages in rheumatoid arthritis

  2000cited by this paper
• Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4).

  1999cited by this paper
• Tumour necrosis factor (TNF) production by T cell receptor‐primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis

  1999cited by this paper
• Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells.

  1999cited by this paper
• Chemoattractant-induced release of elastase by tumor necrosis factor-primed human neutrophils: Auto-regulation by endogenous adenosine

  1999cited by this paper
• IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation.

  1999cited by this paper
• Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation.

  1999cited by this paper
• Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen‐induced arthritis (CIA): a mechanism for methotrexate‐mediated immunosuppression

  1999cited by this paper
• Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis.

  1999cited by this paper
• Adenosine prevents permeability increase in oxidant-injured endothelial monolayers.

  1998cited by this paper
• The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.

  1998cited by this paper
• Neutrophil-derived 5′-Adenosine Monophosphate Promotes Endothelial Barrier Function via CD73-mediated Conversion to Adenosine and Endothelial A2B Receptor Activation

  1998cited by this paper
• Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis.

  1998cited by this paper
• Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention.

  1998cited by this paper
• Activation and Methotrexate‐Mediated Suppression of the TNFα Promoter in T Cells and Macrophages

  1998cited by this paper
• Suppression of macrophage inflammatory protein (MIP)‐1α production and collagen‐induced arthritis by adenosine receptor agonists

  1998cited by this paper
• Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides.

  1998cited by this paper
• Activation and Methotrexate‐Mediated Suppression of the TNFα Promoter in T Cells and Macrophages

  1998cited by this paper
• The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion.

  1998cited by this paper
• Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.

  1998cited by this paper
• Adenosine prevents permeability increase in oxidant-injured endothelial monolayers.

  1998cited by this paper
• Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction.

  1998cited by this paper
• Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis.

  1997cited by this paper
• Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes. A mechanism for methotrexate‐induced nodulosis in rheumatoid arthritis

  1997cited by this paper
• The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study.

  1997cited by this paper
• Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis.

  1997cited by this paper
• Endogenous Adenosine Curtails Lipopolysaccharide‐Stimulated Tumour Necrosis Factor Synthesis

  1997cited by this paper
• The use of folates concomitantly with low-dose pulse methotrexate.

  1997cited by this paper
• Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response.

  1996cited by this paper
• Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells.

  1996cited by this paper
• Hepatic Hepatitis C Virus RNA in Chronic Hepatitis C

  1996cited by this paper
• In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients.

  1996cited by this paper
• FOLIC ACID AND METHOTREXATE IN RHEUMATOID ARTHRITIS. AUTHORS' REPLY

  1996cited by this paper
• Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha.

  1996cited by this paper
• Folic acid and methotrexate in rheumatoid arthritis.

  1996cited by this paper
• Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits.

  1996influential reference
• Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice.

  1996cited by this paper
• Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors.

  1996cited by this paper
• Stimulation of human umbilical vein endothelial cell proliferation by A2‐adenosine and β2‐adrenoceptors

  1995cited by this paper
• Folate supplementation and methotrexate.

  1995cited by this paper
• Inhibition of LPS-induced TNF alpha production in human monocytes by adenosine (A2) receptor selective agonists.

  1995cited by this paper
• Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins.

  1995cited by this paper
• Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis

  1994cited by this paper
• Associations of IgA and IgA-rheumatoid factor with disease features in patients with rheumatoid arthritis.

  1994cited by this paper
• Differential regulatory effects of adenosine on cytokine release by activated human monocytes.

  1994cited by this paper
• Methotrexate for Rheumatoid Arthritis

  1994cited by this paper
• One year treatment with low dose methotrexate in rheumatoid arthritis: Effect on class specific rheumatoid factors

  1993cited by this paper
• Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function.

  1993cited by this paper
• Levels of urinary polyamines in patients with rheumatoid arthritis.

  1993cited by this paper
• Mechanism of Action of Methotrexate: Experimental Evidence that Methotrexate Blocks the Binding of Interleukin 1β to the Interleukin 1 Receptor on Target Cells

  1993cited by this paper
• Adenosine stimulates proliferation of human endothelial cells in culture.

  1993cited by this paper
• Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 (Cd11b/CD18) expression on FMLP-stimulated neutrophils.

  1993cited by this paper
• The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

  1993cited by this paper
• Occupancy of G alpha s-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil.

  1992cited by this paper
• The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis.

  1992influential reference
• Regulation of IL‐2 production by mononuclear cells from rheumatoid arthritis synovial fluids

  1992cited by this paper
• Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis.

  1992cited by this paper
• Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate.

  1992cited by this paper
• Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors.

  1992influential reference
• IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis

  1991cited by this paper
• Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat.

  1991cited by this paper
• Potentiation of leukotriene B4-mediated inflammatory response by the adenosine antagonist, 8-phenyl theophylline.

  1991cited by this paper
• Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport.

  1991cited by this paper
• Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells.

  1991cited by this paper
• The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes.

  1990cited by this paper
• The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine.

  1990cited by this paper
• Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory.

  1990cited by this paper
• The effects of methotrexate on the production and activity of interleukin-1.

  1989cited by this paper
• Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis.

  1989cited by this paper
• Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury.

  1989cited by this paper
• Antiproliferative effects of methotrexate on peripheral blood mononuclear cells.

  1989cited by this paper
• Oxidants, inflammation, and anti‐inflammatory drugs

  1988cited by this paper
• Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis.

  1988cited by this paper
• Effect of antiarthritic drugs on the enhanced interleukin-1 (IL-1) production by macrophages from adjuvant-induced arthritic (AA) rats

  1987cited by this paper
• Immunologic studies of rheumatoid arthritis patients treated with methotrexate.

  1987cited by this paper
• Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate.

  1987cited by this paper
• Dynamics of chemotactic peptide-induced superoxide generation by human monocytes

  1987cited by this paper
• Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide.

  1986cited by this paper

• Can Phagocytosis, Neutrophil Extracellular Traps, and IFN-α Production in Systemic Lupus Erythematosus Be Simultaneously Modulated? A Pharmacological Perspective

  2026influential citation
• Beyond rheumatology: Reconsidering methotrexate for Crohn’s disease in the biologic era

  2026cites this paper
• Triple drug co-delivery within nanosystems for synergistic anti-infective, anti-inflammatory, antinociceptive and neuroregenerative therapeutic effects: a focus on pharmacological and nanotechnological aspects.

  2026cites this paper
• Evaluation of T-Cell Responses Following Sequential Vaccination with PCV13 and PPSV23 Against Streptococcus pneumoniae in Patients with Psoriasis

  2025cites this paper
• Ulceration in Dermatophyte Infection in Methotrexate Toxicity: Hitherto Unkown

  2025cites this paper
• Methotrexate Exhibits a Dual Role in Regulation of CD4+ T Follicular Helper (Tfh) Cell Differentiation and Activity

  2025cites this paper
• Novel methotrexate long-acting system using ambroxol coating and hydroxypropyl methylcellulose encapsulation for preferential and enhanced lung cancer efficiency

  2025cites this paper
• Evaluation of Genetic Marker Polymorphisms (MTHFRC677T and ABCC2 C) for Predicting Methotrexate Toxicity in Psoriasis Patients in Egypt: A Case‐Control Study

  2025cites this paper
• Efficacy of oral metronomic chemotherapy in the management of head and neck squamous cell carcinoma—a systematic review

  2025cites this paper
• Innovative Therapies and Strategies for Rheumatoid Arthritis.

  2025cites this paper
• Cubosome-dissolving microneedle system enhances the anti-psoriatic efficacy of a synergistic combination of methotrexate and cyclosporine.

  2025cites this paper
• Pharmacogenetics of graft-versus-host disease: a path to personalized medicine.

  2025cites this paper
• Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis

  2024cites this paper
• The effect of adjuvant Mitomycin C during vitrectomy on functional and anatomical outcomes in patients with severe diabetic tractional retinal detachment

  2024cites this paper
• Evaluation of the Renoprotective Effects of Valsartan in Methotrexate-Induced Acute Kidney Injury in Rats

  2024cites this paper
• Investigating the Anti-inflammatory Effect of Quinoline Derivative: N1-(5-methyl-5H-indolo[2,3-b]quinolin-11-yl)benzene-1,4-diamine Hydrochloride Loaded Soluble Starch Nanoparticles Against Methotrexate-induced Inflammation in Experimental Model

  2024influential citation
• Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil- filled eyes: pharmacokinetics, safety, and optimal dosage.

  2024cites this paper
• Pharmacogenetics of therapies in rheumatoid arthritis: An update.

  2024cites this paper
• Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients

  2024cites this paper
• Pharmacogenetic Basis of Response Fluctuations to Methotrexate in Rheumatoid Arthritis: A Narrative Review.

  2024cites this paper
• Hyaluronic acid/silk fibroin nanoparticles loaded with methotrexate for topical treatment of psoriasis

  2024cites this paper
• Relationship between the efficacy and adverse effects of methotrexate and gene polymorphism

  2024cites this paper
• Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models.

  2023cites this paper
• Case Report: Insulin hypersensitivity in youth with type 1 diabetes

  2023cites this paper
• The Combined Effect of Curcumin and Crocin on the Reduction of Inflammatory Responses in Arthritic Rats.

  2023cites this paper
• Whey protein concentrate ameliorates the methotrexate-induced liver and kidney damage

  2023cites this paper
• Gallic Acid Protects Against Methotrexate - Induced Intestinal Mucositis; Oxidative Stress, Histopathology and Inflammatory Status

  2023cites this paper
• Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study

  2023cites this paper
• O/W microemulsion and hydrogel formulation of methotrexate and comparison of releasing studies

  2023cites this paper
• Antibodies for β2-Microglobulin and the Heavy Chains of HLA-E, HLA-F, and HLA-G Reflect the HLA-Variants on Activated Immune Cells and Phases of Disease Progression in Rheumatoid Arthritis Patients under Treatment

  2023cites this paper
• Lipid Nanocapsule: A Novel Approach to Drug Delivery System Formulation Development.

  2023cites this paper
• Personalized medicine in rheumatoid arthritis: Combining biomarkers and patient preferences to guide therapeutic decisions.

  2023cites this paper
• Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis.

  2022cites this paper
• Reprogrammed siTNFα/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy

  2022cites this paper
• Overview of Methotrexate Toxicity: A Comprehensive Literature Review

  2022cites this paper
• Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities

  2022cites this paper
• Immunosuppressants

  2022cites this paper
• Immunologic underpinnings and treatment of morphea

  2022cites this paper
• Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma

  2022cites this paper
• ATIC-Associated De Novo Purine Synthesis Is Critically Involved in Proliferative Arterial Disease

  2022cites this paper
• Bioavailability, anti-inflammatory and anti-arthritic effect of Acetyl Keto Boswellic acid and its combination with methotrexate in an arthritic animal model.

  2022cites this paper
• Extracellular vesicle-guided in situ reprogramming of synovial macrophages for the treatment of rheumatoid arthritis.

  2022cites this paper
• Apoptotic body-inspired nanoparticles target macrophages at sites of inflammation to support an anti-inflammatory phenotype shift.

  2022cites this paper
• Methotrexate

  2022cites this paper
• Immunometabolism: An Emerging Target for Immunotherapies to Treat Rheumatoid Arthritis

  2021cites this paper
• Berberine and/or zinc protect against methotrexate-induced intestinal damage: Role of GSK-3β/NRF2 and JAK1/STAT-3 signaling pathways.

  2021cites this paper
• Nanotechnology for Targeted Therapy of Atherosclerosis

  2021cites this paper
• Cytotoxic Lesion in the Splenium of Corpus Callosum Secondary to Subacute Methotrexate Neurotoxicity

  2021cites this paper
• Treatment and Evaluation Advances in Leprosy Neuropathy

  2021cites this paper
• Patient's experiences of the barriers and facilitators to Methotrexate.

  2021cites this paper
• Comparative EPR Study on the Scavenging Effect of Methotrexate with the Isomers of Its Photoswitchable Derivative

  2021cites this paper
• Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy

  2021cites this paper
• Punicalagin Reverses Methotrexate-Induced Nephrotoxicity by Attenuating Oxidative Stress, Inflammation and Apoptosis

  2021cites this paper
• Transdermal release of methotrexate by cationic starch/poly(vinyl alcohol)-based films as an approach for rheumatoid arthritis treatment.

  2021cites this paper
• Risk of Chronic Obstructive Pulmonary Disease Exacerbation in Patients Who Use Methotrexate—A Nationwide Study of 58,580 Outpatients

  2021cites this paper
• Methotrexate-Induced Leukocytoclastic Vasculitis

  2021cites this paper
• Short-term systemic methotrexate administration in rats induces astrogliosis and microgliosis.

  2021cites this paper
• Introduction: specific disease areas

  2021cites this paper
• The effects of drug transporters on the efficacy of methotrexate in the treatment of rheumatoid arthritis.

  2021cites this paper
• Subkutanes Methotrexat bei Morbus Hailey‐Hailey: zwei Fallberichte und Literaturübersicht

  2021cites this paper
• Clinical efficiency of narrowband-ultraviolet B phototherapy and methotrexate therapy and their effects on serum tumor necrosis factor-alpha in patients with cutaneous lichen planus

  2021cites this paper
• Hepatocorbidity in psoriasis

  2021cites this paper
• Interaction analysis of anti-cancer drug Methotrexate with bcl-2 promoter stabilization and its transcription regulation

  2021cites this paper
• Effect of methotrexate and its photodegradation products on the temperature induced denaturation of human serum albumin.

  2020cites this paper
• Corneal Epithelial Toxicity after Intravitreal Methotrexate Injection for Vitreoretinal Lymphoma: Clinical and In Vitro Studies

  2020cites this paper
• Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue remodeling in psoriasis.

  2020cites this paper
• Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics

  2020cites this paper
• Subcutaneous methotrexate for Hailey‐Hailey disease: two case reports and review of the literature

  2020cites this paper
• Intravitreal Injections of Bevacizumab Plus Methotrexate versus Bevacizumab Alone for the Treatment of Diabetic Macular Edema: A Randomized, Sham-Controlled Trial

  2020cites this paper
• Targeting Inflammation After Myocardial Infarction

  2020cites this paper
• Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis

  2020cites this paper
• Perceptions of primary care physicians about early diagnosis of rheumatoid arthritis and methotrexate monitoring

  2020cites this paper
• Joint Aad-Npf Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies.

  2020cites this paper
• Weak Interaction of the Antimetabolite Drug Methotrexate with a Cavitand Derivative

  2020cites this paper
• Molecular mechanism of action and pharmacokinetic properties of methotrexate

  2020cites this paper
• Intra-silicone Oil Injection of Methotrexate in Retinal Reattachment Surgery for Proliferative Vitreoretinopathy

  2020cites this paper
• Lower Extremity Non-Blanchable Purpura Secondary to Methotrexate Toxicity: A Case Report.

  2020cites this paper
• Management of Chronic Urticaria

  2020cites this paper
• Liver rheumatoid nodules imitating liver malignancy: a rare occurrence

  2020cites this paper
• Do we need to fear methotrexate?

  2020cites this paper
• The Protective Role of Ursodeoxycholic Acid versus Seleniumon The Methotrexate Hepatotoxicity in Adult Male Albino Rat: Histological, Immunohistochemical and Histomorphmetric Study

  2020cites this paper
• Protective effect of a new hyaluronic acid -carnosine conjugate on the modulation of the inflammatory response in mice subjected to collagen-induced arthritis.

  2020cites this paper
• P.649 Memory impairments and astroglial and microglial reactions caused by short-term methotrexate administration

  2020cites this paper
• Neutrophils Enable Local and Non‐Invasive Liposome Delivery to Inflamed Skeletal Muscle and Ischemic Heart

  2020cites this paper
• Therapeutic Efficacy and Safety of Methotrexate in Moderate-to-Severe Atopic Dermatitis: A Retrospective Study of Korean Patients at Tertiary Referral Hospital

  2020cites this paper
• Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice.

  2020cites this paper
• Protective effects of Glycyrrhiza glabra supplementation against methotrexate-induced hepato-renal damage in rats: an experimental approach.

  2020cites this paper
• A novel indomethacin/methotrexate/MMP-9 siRNA in situ hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis.

  2020cites this paper
• A Rationally Designed Micellar Nanocarrier for the Delivery of Hydrophilic Methotrexate in Psoriasis Treatment.

  2020cites this paper
• Applications of Lipid Core Nanocapsules: Novel Drug Delivery System

  2020cites this paper
• Review of pharmacotherapeutic treatments for primary sclerosing cholangitis.

  2019cites this paper
• ANALYSIS OF EFFECTS OF METHOTREXATE IN COMBINATION WITH METHYLPREDNISOLONE FOR SPINAL CORD INJURY IN PAKISTAN

  2019cites this paper
• AN EXPERIMENTAL RESEARCH TO DESIGN AND IDENTIFY THE EFFECTS OF LOW-DOSE UNITREXATE IN SECONDARY SPINAL CORD INJURIES

  2019cites this paper
• A COMPREHENSIVE STUDY ON THERAPEUTIC EFFECTS OF LOW DOSE UNITREXATE IN NEUROPATHOLOGICAL DISORDERS

  2019cites this paper
• Diagnostic and therapeutic challenges in inflammatory eye diseases

  2019cites this paper
• Immunotherapy on Neurodegenerative Diseases: Mini Review

  2019cites this paper
• Serum Soluble Interleukin-2 Receptor Is a Biomarker for Pneumocystis jirovecii Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy.

  2019cites this paper
• Methotrexate: CirtIfied for Preventing Atherosclerotic Events?

  2019cites this paper
• Perspective and Potential of A2A and A3 Adenosine Receptors as Therapeutic Targets for the Treatment of Rheumatoid Arthritis.

  2019cites this paper
• Potential Anti-Inflammatory Effects of the Egyptian Scorpion (Androctonus amoreuxi) Venom in Rheumatoid Rat Model

  2019cites this paper